Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
...And this is also true. "Alternative facts"?
This is true. From the 10Q:
The trial is on partial clinical hold for screening of new patients for further enrollment; however, over 300 of the planned 348 patients are enrolled in the trial, and the patients already in the trial have continued to be treated in accordance with the trial protocol, without interruption. The Company is in ongoing dialog with regulators in regard to the partial hold.
Really? In case you did not notice shareholders are being diluted into oblivion EVEN with all the "great news". Powers appears to be just about out of cash again and another horrible deal may be on the way.
I don't see any official filing on that press release??
Nobody can deny it but it can be clarified, and i think Chinatown did a good job of it. Not a reason in the world Powers couldn't hold a cc for clarification.
Hundreds of post here and barely if any a mention of Woodford. I find that remarkable.
"Very clear" ...And you really don't think that had anything to do with Woodford or the SEC?
Doesn't pass the sniff test does it? But they're buying! Lol
...And if they get hit with the flu again say goodbye to that! Lol.
WHERE ARE THE BUYERS?
I'd bet just about every fund manager would likely have a chat with Woodford before dipping their toe in. But you people can ignore him and his importance to your detriment.
Here's how i think it went down:
Woodford, after publicly scolding NWBO on poor governance, puts a call into the SEC.
SEC begins an inquiry.
Powers forced into transparency request the FDA lift the halt since no more patients will be recruited anyway, and so issues this pr.
FDA complies.
I think that's where we are now. What's to come?
What about a reverse split, does she still need shareholder approval?
I'm sure Feuerstein will shine some light on this latest information. And let's not forget the SEC "inquiry". He seems to know something.
"For all we know, the FDA simply acknowledged the company decision to not pursue the final enrollment and therefore removed their ban from doing so. "
That's how i see it too.
Is the property in England part of the deal?
How many more shares outstanding and warrants now?
The past lousy volume and cash raise can tell you a lot. Big Pharma was not making offers. Why?
Woodford must force a board seat here to preserve his investment, imo.
No no no....You still don't get it. Sure there's plenty of good people involved but they don't care about shareholders. Powers should but...NWBO is out of money and more dilution sure to come. Reverse split in the air. DCVax may do some good eventually but CURRENT shareholders will likely not see a dime.
Funny, Woodford seems to feel mislead. I guess he wasn't really following though. Lol.
Correct. Take a look at Peregrine, CYTR, many others...All the same game plan.
What was weird?
Actually over the years I've found with boards like this expressing overwhelming positivity with just a few doubters, that the doubters are almost always right! ...I suppose it could have to do with pushing the doubters away too where the board is unbalanced??
Precisely. And people running these schemes aren't typically in the habit of giving money back. Enter the Reverse Split; Why waste all that fine talent and experience when they can do it again and again and again?
"I also applaud her resolute to see the trial to the very end to gain as much and as many data as possible in a blinded way. "
Yes, just as Woodford and his $100 plus million did. What if she's just collecting a nice salary and not really doing much at all (maybe lots more with Cognate?) except finding funds to for the university?
Actually that was a trick question! I think they'll be antother awful cash raise but we may never see results.
It's one thing to wait but it's an entirely other thing to wait while CEO, CFO, COB, Bookkeeper Powers, does horrendous cash raises. Think!
Of course it does. There's no excuse to exclude interim analysis. At the very least just for ongoing biomarker data.
Keep them in the dark while ever lower cash raises totals nice sums.
In these schemes it's the universities drawing in much need cash to conduct research via the "partner" sponsor's shareholders. So I fail to see how the university is the one being scammed??
As a possibility, what if the university isn't following trial protocol and tiny-under resourced-Northwest looks the the other way? You could imagine where this might lead and how shareholders would find themselves lost in the dark.
$30,000 of hot action so far this morning! Lol.
Would've made a nice PR, if it really meant anything. Too bad, I guess Powers is still down with the flu.
...Many sites show the DCVax study was last verified in 2014 so...
I bet that video is from 2013. There's a later 2016 video where she talks about Optune therapy. No mention of DCVax. You can tell by how she's talking the DCVax trial was over a while ago but she's only interested in the data.
Can't Toucan Capitaless step in the save them?
Well said, thank you.
Hmm, yes I see. I did enough reading myself. Seems Toucan got its head handed to it betting on Stem cells and NanoTech. Both funds appear closed.
Toucan and Powers reminds me very much of the Roswell Capital story and the owner who "saved" the small biotech, Techniclone. In hindsight, one really has to wonder who saved who?
Can someone please tell me why if Toucan is doing such good work did NWBO just do such a lousy cash raise? Thanks.
Toucan Capital Fund II, L.P. is a $120 million venture capital fund (SBIC) focused on seed and early-stage life science and advanced technology investments. Toucan Capital Corp. launched its first fund in 1997 and began investing its current fund in August of 2001. Toucan invests nationwide and is one of the largest and most active venture capital funds in seed and early-stage life science. Toucan has also been an early investor in nanotechnology. Toucan is especially active in the mid-Atlantic region, one of the richest markets in the country for life science and certain advanced technologies, and a market that has generally been underserved by venture capital.
Toucan usually serves as the lead or co-lead investor and takes an active, hands-on role working closely with company management to help build its portfolio companies. For example, Toucan often assists its portfolio companies in building and strengthening their intellectual property base, formulating partnering and regulatory strategies, and ensuring that commercialization and payment/reimbursement issues are addressed from the earliest stages of the company's development.
Can anyone please advise me on the CEO's performance record with her company, Toucan Capital?
Thanks.
Why doubt it? Happens all the time. Just look at the pay to play deals Peregrine made over its history.
Do you think Woodford will just sit back and watch that happen?